Intended for healthcare professionals


Tell women about long term breast cancer risk with HRT, drug agency tells doctors

BMJ 2019; 366 doi: (Published 02 September 2019) Cite this as: BMJ 2019;366:l5350
  1. Elisabeth Mahase
  1. The BMJ

The UK drug regulator has asked trusts, GPs, and hospital doctors to ensure women are told about the increased risk of breast cancer associated with menopausal hormone therapy (MHT)—commonly referred to as hormone replacement therapy (HRT).1

The advice from the Medicines and Healthcare Products Regulatory Agency (MHRA) followed research recently published in the Lancet, which found that the longer women take MHT, the higher their risk …

View Full Text

Log in

Log in through your institution


* For online subscription